The organizations will assess the efficacy of various treatment combinations using three of Pfizer’s investigational immunotherapies, among other drugs, through six different clinical trials.
An MD Anderson-Pfizer joint steering committee will oversee the trials, most of which will launch in late 2017.
“This alliance aims to define patients with solid tumors who may benefit from immunotherapy and to develop therapy resistance strategies,” said Aung Naing, MD, associate professor of investigational cancer therapeutics at MD Anderson. “Our comprehensive approach will allow us to study new combinations of immunotherapy and standard therapies for patients with solid tumors in need of new treatment options.”
More articles on supply chain:
How this movie studio is challenging blood draw restrictions
Why pharmaceutical products in the US don’t include braille labeling
Abbott earns FDA approval for MRI-compatible defibrillator
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
